Shares of Acadia Pharma (NASDAQ: ACAD ) surged higher on Tuesday, after the company said its antipsychotic drug showed positive results in patients with Parkinson's. Anyone holding shares of Acadia greatly benefitted, as the biotech more than doubled -- up over 140 percent at one point. The study met its primary